According to the guidelines, chemotherapy is generally recommended for HR + HER2- breast carcinomas with rapid disease and visceral involvement, as a faster response to chemotherapy is expected than to endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.